Brief: Ascentage Pharma Group International Says U.S. FDA Granted APG-2575 Orphan Drug Designation
05/01/2021 02:09
Jan 5 (Reuters) - Ascentage Pharma Group International
6855.HK :
* US FDA GRANTED APG-2575 ORPHAN DRUG DESIGNATION FOR
TREATMENT OF
PATIENTS WITH ACUTE MYELOID LEUKEMIA
Source text for Eikon: ID:nPn7N6w6va
Further company coverage: 6855.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up